Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Crawling Now, Sprinting Later: Analyst Foresees Major Bitcoin Rally
-
Denali Therapeutics Down After Proposing To Sell $250 Million Of Shares
-
Cryptos Subdued But Bitcoin Firm Above $30k
-
Bitcoin Behemoth: Whale Gathers Accumulated $500 Million in BTC Year-to-Date to Sit on Massive Unrealized Gains
-
Peter Thiel’s Fund Cashed Out $1.8 Billion From Bitcoin Before 2022’s Crash